Financial plays

Naturex targets acquisitions as profits rise

Naturex targets acquisitions as profits rise

By Shane Starling

French botanicals supplier has seen profits rise 28% to €9.7m in the first half of 2011 compared to H1 2010, and says its policy of seeking acquisitions remains unchanged.

Dairy prices to soften, says Glanbia

Dairy prices to soften, says Glanbia

By Helen Glaberson

A modest weakening in dairy prices is expected, forecast Glanbia, as the company posted a profit jump in its half year results.

Frutarom profits dip as raw material costs rise

Frutarom profits dip as raw material costs rise

By Shane Starling

Israel-based flavours, botanicals and speciality ingredients player Frutarom has reported lower profits in Q2, with raw material hikes cited as the principal cause.

Profits are up 6.1% at Kerry for H1,

Kerry delivers “solid” H1 with 6% profit hike to €214m

By Shane Starling

Irish dairy and ingredients group Kerry has turned in a”solid” first half of 2011 that saw it increase volumes, weather raw material price hikes, and see success in a “go-to-market” functional ingredient strategy as profits jumped 6.1% on 2010 figures.

DSM on Vitatene, Martek and its investment “shortlist”

Disptaches from Vitafoods Europe 2011

DSM on Vitatene, Martek and its investment “shortlist”

By Shane Starling

DSM’s head of global marketing in human nutrition and health, Gareth Barker, explains why it has bought a carotenoid supplier (approval permitting), how the Martek acquisition is progressing, and why the company is not finished spending yet.

DuPont succeeds in Danisco bid

DuPont succeeds in Danisco bid

By Caroline Scott-Thomas

US chemical group DuPont has successfully completed its tender offer for Danisco, as 92.2 percent of outstanding shares in the Danish food ingredients firm were tendered by Friday’s deadline, DuPont said on Monday.

DSM reports successful tender offer for Martek

DSM reports successful tender offer for Martek

By Mike Stones

Royal DSM’s acquisition of Martek Biosciences Corporation has moved a step closer to finalisation with the news that its tender offer to buy all of the company’s outstanding shares of common stock at a price of $31.50 (about €24) per share has proved...

Follow us

Featured Events

View more

Products

View more

Webinars